BNTX logo

BioNTech SE (BNTX)

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell...

NASDAQHealthcareBiotechnologyUSA

公司简介

股票代码
BNTX
ISIN代码
US09075V1026
货币
US Dollar (USD)
IPO日期
2019-10-10

联系信息

公司地址
An der Goldgrube 12, Mainz, Germany, 55131
联系电话
49 6131 9084
公司网站
https://www.biontech.de
财年结束
December

财务亮点

市值
$999,999.99
毛利润(TTM)
$999,999.99
资产回报率(TTM)
-4.18%
EBITDA
$-999,999.99
收入(TTM)
$999,999.99